Imara completed dosing patients in the IMR-687 Phase 2a clinical trial in patients with SCD during the third quarter of 2020 and plans to report top-line data late in the fourth quarter of 2020 ...

The presentation will be available on the Investors section of the Imara website. About IMR-261 IMR-261 (formerly CXA-10) is an activator of nuclear factor erythroid 2–related factor 2, or Nrf2.

Imara reports additional pre-clinical and Phase 1 data for lead compound, IMR-687, at the 6th Annual Sickle Cell Therapeutics Conference in New York.

Arix Bioscience plc Imara Announces Interim Analysis Data From Forte Phase 2b Clinical Trial Of Tovinontrine (Imr-687) In Transfusion-Dependent Subjects With Beta-Thalassemia LONDON, 17 November ...